Compare FMC Corp (FMC) vs Globus Medical Inc. Class A Common Stock (GMED) Price & Performance

FMC trades at $8.09, down 2.76% on the day, with a bearish technical signal and weak fundamentals including a net income margin of -84.83% and negative ROE of -91.47% for 2025. Recent earnings show mixed results with Q2 2026 beating estimates, but revenue has declined from $5.8B in 2022 to $3.47B in 2025. Positive developments include a regulatory filing for rimisoxafen in Brazil and a minority equity investment by Tessenderlo Group, yet cash flow from operations remains negative.

The outlook is cautious; while analyst consensus is a buy with a $14.20 price target, high debt and cyclical industry headwinds pose significant risks. Aggressive deleveraging efforts may improve financial stability, but persistent revenue declines and negative profitability underscore substantial challenges for near-term recovery.

Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.

GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.